Nextage Therapeutics Ltd
TASE:NXTG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Nextage Therapeutics Ltd
TASE:NXTG
|
IL |
Multiples-Based Value
The Multiples-Based Value of one NXTG stock under the Base Case scenario is 3.94 ILS. Compared to the current market price of 64.1 ILS, Nextage Therapeutics Ltd is Overvalued by 94%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
NXTG Competitors Multiples
Nextage Therapeutics Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IL |
N
|
Nextage Therapeutics Ltd
TASE:NXTG
|
48.8m ILS | 118.2 | -14.9 | -14.6 | -14.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
367.6B USD | 6 | 87.8 | 14.6 | 20.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.2B USD | 5.1 | 24.5 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
172.5B USD | 5.9 | 20.3 | 12.7 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.8B USD | 9.2 | 28 | 21 | 22 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 5.5 | 17.6 | 13 | 14.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.2B EUR | 11.9 | 38.2 | 41.3 | 42.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.1B AUD | 3 | 32.9 | 11.1 | 13.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |